Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|The Oncologist|2015Cited by 114
Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast CancerValentina Guarneri, PierFranco Conte, Daniele Generali et al.|Journal of Clinical Oncology|2014Cited by 62
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomasSilvia Uccella, Stefano Sacchi, Erika Morsia et al.|Human Pathology|2023Cited by 3
Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous LymphomasSilvia Uccella, Stefano Sacchi, Gaia Goteri et al.|Blood|2022Cited by 0